GNHAY News and Press, Vifor Pharma AG ADR

UBS has upgraded DaVita ( NYSE: DVA ) to buy from neutral citing its ability to deliver EPS growth in the coming years. The firm upped its price target to $117 from $106 (~31% upside based on Thursday's close). Analyst Andrew Mok said he is confident the company can de...

The Swiss Agency for Therapeutic Products (Swissmedic) approved Cara Therapeutics ( NASDAQ: CARA ) and Vifor Fresenius Medical Care Renal Pharma's Kapruvia (difelikefalin) to treat moderate-to-severe pruritus (itching) associated with chronic kidney disease ...

Vifor Fresenius Medical Care Renal Pharma said that England's National Institute for Health and Care Excellence (NICE) recommended Tavneos in combination with a rituximab or cyclophosphamide regimen to treat adult patients with severe, active granulomatosis polyangiitis (GPA)...

CSL's (OTCPK:CSLLY) unit CSL Behring reported provisional results of its tender offer to acquire all publicly held shares of Vifor Pharma (OTCPK:GNHAY) for $179.25/ share in a deal valued at ~$11.7B. CSL's participation at the end of the additional acceptance period on March 22 was a total of...

The second part to my series on the Biotechnology industry will be finding the necessary skills to research companies. The concepts are simple, but the information is sometimes difficult to find, and so I provide some examples. The five companies I analyze are just examples, and u...

CSL BEHRING AG PUBLISHES OFFER PROSPECTUS ON PUBLIC TENDER OFFER FOR ALL PUBLICLY HELD SHARES OF VIFOR PHARMA LTD. Ad hoc release pursuant to Art. 53 LR, Switzerland PR Newswire MELBOURNE, Australia and ST. GALLEN, Switzerland , Jan. 18, 2022 /PRNewswire/...

Vifor Pharma (OTCPK:GNHAY) and its partner American Regent, a Daiichi Sankyo Group company, have reached settlement agreements with Mylan Laboratories and Sandoz that resolve the patent litigation brought in response to Abbreviated New Drug Applications seeking approval by the FDA to market a...

Vifor Pharma (OTCPK:GNHAY) announces the acquisition of Sanifit Therapeutics, a Spanish clinical-stage cardio-renal biopharmaceutical company focused on treatments for end-stage kidney disease patients with progressive vascular calcification disorders, and Inositec AG, a Swiss company, develo...

Cara Therapeutics (NASDAQ:CARA) continues to outperform in the pre-market with a gain of ~23.3% after the company and its Swiss partner Vifor Pharma (OTCPK:GNHAY) secured the FDA approval for KORSUVA (difelikefalin) as a treatment for moderate-to-severe itching in adults with chroni...

Vifor Pharma AG (GNHAF) Q2 2021 Earnings Conference Call August 5, 2021, 8:00 am ET Company Participants Colin Bond - CFO Klaus Jensen - CMO Conference Call Participants Christian Glennie - Stifel James Gordon - JPMorgan Rosie Turner - Barclays Paul Verbraeken - Research Partners Barbora Blah...